Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Access and distribution
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

2 evidence topics · 2 sources

Expanded access

“Requests will be considered on a case-by-case basis.” (opens the source at this quote in a new tab)
“All requests must be submitted by the patient’s treating physician.” (opens the source at this quote in a new tab)

Anticipated patient support

“establishing a comprehensive patient support program” (opens the source at this quote in a new tab)